Lisa Bodei, MD, PhD
Lisa Bodei, M.D., Ph.D., is Director of Targeted Radionuclide Therapy, Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center. Dr. Bodei has extensive expertise in therapeutic and diagnostic applications of nuclear medicine in oncology.
Her clinical research combines therapeutic and diagnostic components of nuclear medicine. She has a specialized interest in peptide receptor radionuclide therapy (PRRT) of gut and lung neuroendocrine tumors, including special investigational and molecular translational analyses to facilitate diagnosis and therapy. Her clinical and research experience includes a broad range of diagnostic endocrine applications in nuclear medicine such as receptor scintigraphy, 68Ga-octreotide PET/TC, 18FDG-PET/CT in oncology, radio-immuno-scintigraphy, and sentinel node scintigraphy.
Dr. Bodei is author or co-author of more than 100 peer-reviewed publications, and serves on the editorial boards of several scientific journals including the Journal of Nuclear Medicine and the European Journal of Nuclear Medicine and Molecular Imaging.
Residency: School of Specialization in Nuclear Medicine, University of Pisa (Italy)
Fellowship: Nuclear Medicine Division, European Institute of Oncology (Milan, Italy)
Board Certification: Nuclear Medicine, University of Pisa (Italy)
MD, University of Pisa (Italy); PhD, Department of Nuclear Medicine and Molecular Imaging, University of Groningen (Netherlands)